Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer's Epogen Biosimilar Retacrit Launches At 33% Off In A US Market Where Amgen's Already Competitive

Nov 15 2018

• By Mandy Jackson

Sterile bottles and ampoules on the dispensing line.Sealed ampoules with medicine.Sterile capsules for injection. Bottles on the bottling line of the pharmaceutical plant.

Related Content

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

Nov 14 2016

Vifor Becomes A 'Pure Play' Pharma

Apr 10 2017

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Sep 20 2017

Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha

Apr 29 2016

J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Sep 13 2018

From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive

Sep 07 2018

Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta

Nov 10 2018

Pfizer Wants FDA To Stop Sponsor Promos From Implying Biosimilars Are Inferior

Aug 28 2018

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

Related Companies

Pfizer Inc.

Amgen, Inc.

Johnson & Johnson

Roche Holding AG

CSL Vifor

Coherus Oncology, Inc.

Viatris Inc.

Additional Topics

Biosimilars Launches Pricing Strategies Market Access Commercial Renal Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window